The estimated Net Worth of Robert W. Hesslein is at least $6.51 Million dollars as of 20 March 2023. Mr. Hesslein owns over 4,410 units of Voyager Therapeutics Inc stock worth over $641,816 and over the last 8 years he sold VYGR stock worth over $2,627,612. In addition, he makes $3,240,960 as Senior Vice President and General Counsel at Voyager Therapeutics Inc.
Sign up
Mr. Hesslein VYGR stock SEC Form 4 insiders trading
Robert has made over 25 trades of the Voyager Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 4,410 units of VYGR stock worth $34,222 on 20 March 2023.
The largest trade he's ever made was selling 18,021 units of Voyager Therapeutics Inc stock on 16 January 2018 worth over $1,158,750. On average, Robert trades about 3,278 units every 77 days since 2016. As of 20 March 2023 he still owns at least 102,200 units of Voyager Therapeutics Inc stock.
You can see the complete history of Mr. Hesslein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Hesslein biography
Robert W. Hesslein is Senior Vice President, General Counsel of the Company since April 2019. Mr. Hesslein was previously the Senior Vice President, General Counsel, and Chief Compliance Officer at Foundation Medicine, Inc., a molecular information company focused on cancer genomics, which is now a subsidiary of Roche, from May 2012 to March 2019. Mr. Hesslein was previously Senior Vice President and Deputy General Counsel at Genzyme, a biotechnology company, which is now a subsidiary of Sanofi, from July 1996 to May 2012. Before Genzyme, from September 1990 to June 1996, Mr. Hesslein was a Second Vice President and Counsel at The New England, a mutual life insurance company. From September 1978 to August 1990, Mr. Hesslein was an associate and subsequently a partner at Csaplar & Bok, a Boston law firm. Mr. Hesslein earned his B.A. from Yale University and his J.D. from The Cornell Law School.
What is the salary of Robert Hesslein?
As the Senior Vice President and General Counsel of Voyager Therapeutics Inc, the total compensation of Robert Hesslein at Voyager Therapeutics Inc is $3,240,960. There are 1 executives at Voyager Therapeutics Inc getting paid more, with Omar Khwaja having the highest compensation of $3,815,770.
How old is Robert Hesslein?
Robert Hesslein is 67, he's been the Senior Vice President and General Counsel of Voyager Therapeutics Inc since 2019. There are 2 older and 13 younger executives at Voyager Therapeutics Inc. The oldest executive at Voyager Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the Exec. Science Advisor & Director.
What's Robert Hesslein's mailing address?
Robert's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC.,, 64 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Insiders trading at Voyager Therapeutics Inc
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1, and Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
What does Voyager Therapeutics Inc do?
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
What does Voyager Therapeutics Inc's logo look like?
Complete history of Mr. Hesslein stock trades at Voyager Therapeutics Inc
Voyager Therapeutics Inc executives and stock owners
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Omar Khwaja,
Chief Medical Officer and Head of Research and Development -
Robert Hesslein,
Senior Vice President, General Counsel -
G. Andre Turenne,
President, Chief Executive Officer, Director -
G. Andre Turenne,
Advisor -
Dr. Omar Khwaja M.D., Ph.D.,
Chief Medical Officer and Head of R&D -
Robert W. Hesslein,
Sr. VP & Gen. Counsel -
james Geraghty,
Independent Director -
Steven Hyman,
Independent Director -
Michael J. Higgins M.B.A.,
Interim CEO, Pres & Chairman -
Dr. Glenn F. Pierce M.D., Ph.D.,
Independent Director, Interim Chief Scientific Officer & Chief Medical Officer -
Dr. Steven M. Paul M.D.,
Exec. Science Advisor & Director -
Nancy Vitale,
Director -
Michelle Smith,
Chief Human Resource Officer -
Kelly Bales,
Senior Vice President, Head of Neuroscience -
Allison Dorval,
Chief Financial Officer -
Robin Swartz,
Chief Operating Officer -
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.,
Pres, CEO & Director -
Julie Burek,
VP of Fin. -
Dr. Mark A. Kay M.D., Ph.D.,
Founder -
Dr. Phillip D. Zamore,
Founder -
Dr. Mark A. Kay,
Founder -
Dr. Guangping Gao,
Founder -
Dr. Krystof Bankiewicz M.D., Ph.D.,
Founder -
Toby Ferguson,
Chief Medical Officer -
Sandell Jacquelyn Fahey,
Chief Legal Officer -
Rock Ventures Iii, L.P.Thir...,
-
Jane Henderson,
Sr. V.P. & CFO, Corp. Dev. -
Wendy L Dixon,
Director -
Jeff Goater,
Chief Financial Officer -
Sanofi,
-
Perry A Karsen,
Director -
Harbor Master Investors (Ca...,
10% owner -
Bernard Ravina,
Chief Medical Officer -
Matthew P. Ottmer,
Chief Operating Officer -
Dinah Ph.D. Sah,
Chief Scientific Officer -
Steven M Paul,
Director -
Andre Turenne,
President & CEO -
Robin Swartz,
Chief Operating Officer -
Biosciences Inc Neurocrine,
10% owner -
Michael J Higgins,
Director -
Mark J Levin,
Director -
Glenn Pierce,
Director -
Julie Burek,
VP, Finance -
Todd Alfred Carter,
Chief Scientific Officer -
Peter P. Pfreundschuh,
Chief Financial Officer -
Rock Ventures Iii, L.P.Thir...,
-
Catherine J Mackey,
Director -
Jude Onyia,
Director -
Grace Colon,
Director -
Capital, Llc Eco R1,
10% owner -
George A Scangos,
Director -
Nathan D. Jorgensen,
Chief Financial Officer